9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Xbp1s-FoxO1 axis governs lipid accumulation and contractile performance in heart failure with preserved ejection fraction

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Heart failure with preserved ejection fraction (HFpEF) is now the dominant form of heart failure and one for which no efficacious therapies exist. Obesity and lipid mishandling greatly contribute to HFpEF. However, molecular mechanism(s) governing metabolic alterations and perturbations in lipid homeostasis in HFpEF are largely unknown. Here, we report that cardiomyocyte steatosis in HFpEF is coupled with increases in the activity of the transcription factor FoxO1 (Forkhead box protein O1). FoxO1 depletion, as well as over-expression of the Xbp1s (spliced form of the X-box-binding protein 1) arm of the UPR (unfolded protein response) in cardiomyocytes each ameliorates the HFpEF phenotype in mice and reduces myocardial lipid accumulation. Mechanistically, forced expression of Xbp1s in cardiomyocytes triggers ubiquitination and proteasomal degradation of FoxO1 which occurs, in large part, through activation of the E3 ubiquitin ligase STUB1 (STIP1 homology and U-box-containing protein 1) a novel and direct transcriptional target of Xbp1s. Our findings uncover the Xbp1s-FoxO1 axis as a pivotal mechanism in the pathogenesis of cardiometabolic HFpEF and unveil previously unrecognized mechanisms whereby the UPR governs metabolic alterations in cardiomyocytes.

          Abstract

          Heart failure with preserved ejection fraction (HFpEF) is a global, major health issue for which no effective therapies are available. Here, the authors discover that the interplay between two transcription factors, Xbp1s and FoxO1, is critical for metabolic adaptation and lipid handling in HFpEF-stressed cardiomyocytes.

          Related collections

          Most cited references53

          • Record: found
          • Abstract: found
          • Article: not found

          Epidemiology of heart failure with preserved ejection fraction

          Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome associated with poor quality of life, substantial health-care resource utilization, and premature mortality. Dunlay and colleagues summarize the epidemiological data on HFpEF, with a focus on the prevalence and incidence of HFpEF in the community as well as associated conditions and risk factors, morbidity and mortality after diagnosis, and quality of life.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction.

            Heart failure (HF) with preserved ejection fraction (HFpEF) is a heterogeneous syndrome. Phenotyping patients into pathophysiologically homogeneous groups may enable better targeting of treatment. Obesity is common in HFpEF and has many cardiovascular effects, suggesting that it may be a viable candidate for phenotyping. We compared cardiovascular structure, function, and reserve capacity in subjects with obese HFpEF, those with nonobese HFpEF, and control subjects.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.

              Heart failure (HF) with preserved ejection fraction (EF; HFpEF) accounts for 50% of HF cases, and its prevalence relative to HF with reduced EF continues to rise. In contrast to HF with reduced EF, large trials testing neurohumoral inhibition in HFpEF failed to reach a positive outcome. This failure was recently attributed to distinct systemic and myocardial signaling in HFpEF and to diversity of HFpEF phenotypes. In this review, an HFpEF treatment strategy is proposed that addresses HFpEF-specific signaling and phenotypic diversity. In HFpEF, extracardiac comorbidities such as metabolic risk, arterial hypertension, and renal insufficiency drive left ventricular remodeling and dysfunction through systemic inflammation and coronary microvascular endothelial dysfunction. The latter affects left ventricular diastolic dysfunction through macrophage infiltration, resulting in interstitial fibrosis, and through altered paracrine signaling to cardiomyocytes, which become hypertrophied and stiff because of low nitric oxide and cyclic guanosine monophosphate. Systemic inflammation also affects other organs such as lungs, skeletal muscle, and kidneys, leading, respectively, to pulmonary hypertension, muscle weakness, and sodium retention. Individual steps of these signaling cascades can be targeted by specific interventions: metabolic risk by caloric restriction, systemic inflammation by statins, pulmonary hypertension by phosphodiesterase 5 inhibitors, muscle weakness by exercise training, sodium retention by diuretics and monitoring devices, myocardial nitric oxide bioavailability by inorganic nitrate-nitrite, myocardial cyclic guanosine monophosphate content by neprilysin or phosphodiesterase 9 inhibition, and myocardial fibrosis by spironolactone. Because of phenotypic diversity in HFpEF, personalized therapeutic strategies are proposed, which are configured in a matrix with HFpEF presentations in the abscissa and HFpEF predispositions in the ordinate.
                Bookmark

                Author and article information

                Contributors
                joseph.hill@utsouthwestern.edu
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                16 March 2021
                16 March 2021
                2021
                : 12
                : 1684
                Affiliations
                [1 ]GRID grid.267313.2, ISNI 0000 0000 9482 7121, Department of Internal Medicine (Cardiology), , University of Texas Southwestern Medical Center, ; Dallas, TX USA
                [2 ]GRID grid.4691.a, ISNI 0000 0001 0790 385X, Department of Advanced Biomedical Sciences, , Federico II University, ; Naples, Italy
                [3 ]GRID grid.6363.0, ISNI 0000 0001 2218 4662, Center for Cardiovascular Research (CCR), Department of Cardiology, , Charité - Universitätsmedizin Berlin, ; Berlin, Germany
                [4 ]GRID grid.452396.f, ISNI 0000 0004 5937 5237, DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, ; Berlin, Germany
                [5 ]GRID grid.419491.0, ISNI 0000 0001 1014 0849, Translational Approaches in Heart Failure and Cardiometabolic Disease, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), ; Berlin, Germany
                [6 ]GRID grid.267313.2, ISNI 0000 0000 9482 7121, Department of Pediatrics, , University of Texas Southwestern Medical Center, ; Dallas, TX USA
                [7 ]GRID grid.267313.2, ISNI 0000 0000 9482 7121, Advanced Imaging Research Center, , University of Texas Southwestern Medical Center, ; Dallas, TX USA
                [8 ]GRID grid.267313.2, ISNI 0000 0000 9482 7121, Harold C. Simmons Comprehensive Cancer, , University of Texas Southwestern Medical Center, ; Dallas, TX USA
                [9 ]GRID grid.417169.c, ISNI 0000 0000 9359 6077, Parkland Health & Hospital System, ; Dallas, TX USA
                [10 ]GRID grid.443909.3, ISNI 0000 0004 0385 4466, Advanced Center for Chronic Diseases (ACCDiS), Faculty of Chemical & Pharmaceutical Sciences & Faculty of Medicine, , Universidad de Chile, ; Santiago, Chile
                [11 ]GRID grid.267313.2, ISNI 0000 0000 9482 7121, Department of Molecular Biology, , University of Texas Southwestern Medical Center, ; Dallas, TX USA
                Author information
                http://orcid.org/0000-0002-7582-7171
                http://orcid.org/0000-0002-1612-2729
                http://orcid.org/0000-0002-9285-7719
                http://orcid.org/0000-0002-3303-0295
                http://orcid.org/0000-0003-0615-7626
                http://orcid.org/0000-0002-9264-2320
                http://orcid.org/0000-0003-4878-891X
                http://orcid.org/0000-0003-4258-1483
                http://orcid.org/0000-0002-7617-3544
                http://orcid.org/0000-0002-5379-1614
                Article
                21931
                10.1038/s41467-021-21931-9
                7966396
                33727534
                81d32e56-6f15-4950-b942-9db9e4cf32c5
                © The Author(s) 2021

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 30 July 2020
                : 9 February 2021
                Funding
                Funded by: FundRef https://doi.org/10.13039/100000050, U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI);
                Award ID: HL-120732
                Award ID: HL-128215
                Award ID: HL-126012
                Award ID: HL-147933
                Award ID: HL-155765
                Award Recipient :
                Funded by: U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
                Funded by: U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
                Funded by: U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
                Funded by: U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
                Categories
                Article
                Custom metadata
                © The Author(s) 2021

                Uncategorized
                cell signalling,heart failure
                Uncategorized
                cell signalling, heart failure

                Comments

                Comment on this article